Equities research analysts expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to report ($0.74) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Collegium Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($0.67) and the lowest estimate coming in at ($0.81). Collegium Pharmaceutical reported earnings per share of ($1.13) during the same quarter last year, which would indicate a positive year over year growth rate of 34.5%. The company is expected to issue its next earnings report on Thursday, November 9th.

On average, analysts expect that Collegium Pharmaceutical will report full year earnings of ($3.00) per share for the current year, with EPS estimates ranging from ($3.38) to ($2.80). For the next financial year, analysts expect that the business will post earnings of ($1.92) per share, with EPS estimates ranging from ($2.41) to ($1.12). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.09. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $4.07 million. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%.

Several research analysts have commented on the stock. Piper Jaffray Companies restated a “buy” rating and issued a $14.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, September 8th. BidaskClub cut shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Jefferies Group LLC restated a “buy” rating and issued a $15.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Finally, HC Wainwright assumed coverage on shares of Collegium Pharmaceutical in a report on Monday, September 11th. They issued a “buy” rating and a $21.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Collegium Pharmaceutical currently has a consensus rating of “Hold” and an average target price of $20.00.

Several institutional investors have recently bought and sold shares of the company. Sectoral Asset Management Inc boosted its holdings in shares of Collegium Pharmaceutical by 41.4% in the second quarter. Sectoral Asset Management Inc now owns 1,808,750 shares of the specialty pharmaceutical company’s stock valued at $22,627,000 after acquiring an additional 529,503 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in shares of Collegium Pharmaceutical by 37.1% in the second quarter. Macquarie Group Ltd. now owns 1,118,691 shares of the specialty pharmaceutical company’s stock valued at $13,995,000 after acquiring an additional 302,892 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Collegium Pharmaceutical by 684.8% in the first quarter. Morgan Stanley now owns 885,268 shares of the specialty pharmaceutical company’s stock valued at $8,906,000 after acquiring an additional 772,464 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Collegium Pharmaceutical by 7.8% in the first quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock valued at $8,113,000 after acquiring an additional 58,398 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Collegium Pharmaceutical by 42.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 640,189 shares of the specialty pharmaceutical company’s stock valued at $6,440,000 after acquiring an additional 191,062 shares in the last quarter. Institutional investors and hedge funds own 83.04% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “-$0.74 EPS Expected for Collegium Pharmaceutical, Inc. (COLL) This Quarter” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/19/0-74-eps-expected-for-collegium-pharmaceutical-inc-coll-this-quarter.html.

Shares of Collegium Pharmaceutical (NASDAQ COLL) traded up 3.33% during midday trading on Monday, reaching $11.78. 498,026 shares of the company were exchanged. The company’s 50-day moving average price is $10.81 and its 200 day moving average price is $10.81. The stock’s market capitalization is $348.29 million. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $18.67.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.